Lin K L, Zhu L, Fu C, Lin Z B, Chen G
Institute of Organ Transplantation, Tongji Hospital, Huazhong University of Science and Technology, Key Laboratory of Organ Transplantation, Ministry of Education, Key Laboratory of Organ Transplantation, Ministry of Public Health, Wuhan 430030, China.
Zhonghua Yi Xue Za Zhi. 2017 Jan 10;97(2):99-103. doi: 10.3760/cma.j.issn.0376-2491.2017.02.004.
To compare the safety and effectiveness between antithymocyte globulin (ATG) and basiliximab in deceased donor renal transplantation within matched groups where paired recipients received graft donations from same donors. A total of 124 cases of deceased donor kidney transplantation performed at Wuhan Tongji Hospital from January 2013 to November 2015 were retrospectively analyzed. Based upon their induction therapies, the recipients receiving graft donations from same donors were divided into two groups, namely ATG group (=62) and basiliximab group (=62). Clinical data were gathered and comparisons were made between the two groups. Delayed graft function (DGF) implicated less patients in the ATG group (11, 17.7%) compared with basiliximab group (21, 33.9%) (=0.040). Duration of DGF was also significantly shorter in the ATG group than in the basiliximab group[(14.92±6.23) vs(20.26±7.89)days, =0.048]. The rates of DGF were 5/18 in the ATG group and 10/15 in the basiliximab group (=0.025), when subgrouping the patients with elevated risk factors (donor age >50 or a history of hypertension or graft cold ischemia time >24 h) for DGF. The acute rejection rates did not differ between the two groups significantly; comparable one-year graft and patient survival were observed between the ATG and basiliximab groups(all >0.05). The duration of DGF and DGF rate after deceased donor renal transplantation is reduced by ATG, when compared with basiliximab. Moreover, in recipients with elevated risk factors for DGF, ATG diminishes DGF incidence significantly.
在配对受者接受来自相同供者的移植物捐赠的匹配组中，比较抗胸腺细胞球蛋白（ATG）和巴利昔单抗在 deceased 供者肾移植中的安全性和有效性。回顾性分析了 2013 年 1 月至 2015 年 11 月在武汉同济医院进行的 124 例 deceased 供者肾移植病例。根据诱导治疗方法，将接受来自相同供者移植物捐赠的受者分为两组，即 ATG 组（n = 62）和巴利昔单抗组（n = 62）。收集临床数据并在两组之间进行比较。与巴利昔单抗组（21 例，33.9%）相比。ATG 组发生移植肾功能延迟恢复（DGF）的患者较少（11 例，17.7%）（P = 0.040）。ATG 组 DGF 的持续时间也明显短于巴利昔单抗组[（14.92±6.23）天 vs（20.26±7.89）天，P = 0.048]。对有 DGF 高风险因素（供者年龄>50 岁或有高血压病史或移植冷缺血时间>24 小时）的患者进行亚组分析时。ATG 组的 DGF 发生率为 5/18，巴利昔单抗组为 10/15（P = 0.025）。两组的急性排斥反应率无显著差异；ATG 组和巴利昔单抗组观察到相似的一年移植肾和受者生存率（均>0.05）。与巴利昔单抗相比，ATG 可缩短 deceased 供者肾移植后 DGF 的持续时间和发生率。此外，在有 DGF 高风险因素的受者中，ATG 可显著降低 DGF 的发生率。
